Literature DB >> 9520474

Recombinant viruses expressing a human malaria antigen can elicit potentially protective immune CD8+ responses in mice.

Y Miyahira1, A García-Sastre, D Rodriguez, J R Rodriguez, K Murata, M Tsuji, P Palese, M Esteban, F Zavala, R S Nussenzweig.   

Abstract

Extensive studies on protective immunity to rodent malaria provided the basis for the current experiments in which mice were immunized with recombinant (re) influenza and vaccinia viruses expressing selected sequences of the circumsporozoite (CS) protein of the human malaria parasite Plasmodium falciparum. Mice of different H-2 haplotypes immunized with re influenza viruses expressing the immunodominant B cell epitope of this CS protein produced high titers of antibodies to the parasite. A cytotoxic T lymphocyte epitope of the CS protein of P. falciparum, PF3, recognized by CD8+ T cells of H-2(k) mice, was expressed in a re vaccinia virus (VacPf) and a re influenza virus (FluPf). Immunization of mice with either FluPf or VacPf elicited a modest CS-specific CD8+ T cell response detected by interferon gamma secretion of individual immune cells. Priming of mice with FluPf, followed by a booster with VacPf, resulted in a striking enhancement of this T cell response. The reverse protocol, i.e., priming with VacPf followed by a booster with FluPf, failed to enhance the primary response. VacPf also greatly enhanced the primary response of mice injected with P. falciparum sporozoites or with a lipopeptide containing PF3. A booster with FluPf also amplified the response of lipopeptide- or sporozoite-primed mice but less than a VacPf booster did. Although mice are not susceptible to infection by P. falciparum sporozoites, we demonstrated that administration of two distinct immunogens expressing PF3 elicited activated, extravasating CS-specific T cells that protected against an intracerebral VacPf challenge.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9520474      PMCID: PMC19944          DOI: 10.1073/pnas.95.7.3954

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  21 in total

Review 1.  Rationale for the development of an engineered sporozoite malaria vaccine.

Authors:  V Nussenzweig; R S Nussenzweig
Journal:  Adv Immunol       Date:  1989       Impact factor: 3.543

2.  Recombinant vaccinia viruses and the development of immunization strategies using influenza virus.

Authors:  P C Doherty; W Allan; D B Boyle; B E Coupar; M E Andrew
Journal:  J Infect Dis       Date:  1989-06       Impact factor: 5.226

3.  Cytotoxic T cells specific for the circumsporozoite protein of Plasmodium falciparum.

Authors:  S Kumar; L H Miller; I A Quakyi; D B Keister; R A Houghten; W L Maloy; B Moss; J A Berzofsky; M F Good
Journal:  Nature       Date:  1988-07-21       Impact factor: 49.962

4.  The circumsporozoite protein gene from NF54, a Plasmodium falciparum isolate used in malaria vaccine trials.

Authors:  P Caspers; R Gentz; H Matile; J R Pink; F Sinigaglia
Journal:  Mol Biochem Parasitol       Date:  1989-06-15       Impact factor: 1.759

5.  Multiple T helper cell epitopes of the circumsporozoite protein of Plasmodium berghei.

Authors:  P J Romero; J P Tam; D Schlesinger; P Clavijo; H Gibson; P J Barr; R S Nussenzweig; V Nussenzweig; F Zavala
Journal:  Eur J Immunol       Date:  1988-12       Impact factor: 5.532

6.  Characterization of two distinct major histocompatibility complex class I Kk-restricted T-cell epitopes within the influenza A/PR/8/34 virus hemagglutinin.

Authors:  K G Gould; H Scotney; G G Brownlee
Journal:  J Virol       Date:  1991-10       Impact factor: 5.103

Review 7.  T cell responses to pre-erythrocytic stages of malaria: role in protection and vaccine development against pre-erythrocytic stages.

Authors:  E H Nardin; R S Nussenzweig
Journal:  Annu Rev Immunol       Date:  1993       Impact factor: 28.527

8.  Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites.

Authors:  D A Herrington; D F Clyde; G Losonsky; M Cortesia; J R Murphy; J Davis; S Baqar; A M Felix; E P Heimer; D Gillessen
Journal:  Nature       Date:  1987 Jul 16-22       Impact factor: 49.962

9.  The in vivo cytotoxic activity of CD8+ T cell clones correlates with their levels of expression of adhesion molecules.

Authors:  M Rodrigues; R S Nussenzweig; P Romero; F Zavala
Journal:  J Exp Med       Date:  1992-04-01       Impact factor: 14.307

10.  Monovalent fragments (Fab) of monoclonal antibodies to a sporozoite surface antigen (Pb44) protect mice against malarial infection.

Authors:  P Potocnjak; N Yoshida; R S Nussenzweig; V Nussenzweig
Journal:  J Exp Med       Date:  1980-06-01       Impact factor: 14.307

View more
  26 in total

1.  Expression of the surface glycoproteins of human parainfluenza virus type 3 by bovine parainfluenza virus type 3, a novel attenuated virus vaccine vector.

Authors:  A A Haller; T Miller; M Mitiku; K Coelingh
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

2.  Profound protection against respiratory challenge with a lethal H7N7 influenza A virus by increasing the magnitude of CD8(+) T-cell memory.

Authors:  J P Christensen; P C Doherty; K C Branum; J M Riberdy
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

3.  Immunogenicity and protective efficacy of replication-incompetent influenza virus-like particles.

Authors:  Tokiko Watanabe; Shinji Watanabe; Gabriele Neumann; Hiroshi Kida; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

Review 4.  RNA virus vectors: where are we and where do we need to go?

Authors:  P Palese
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-27       Impact factor: 11.205

Review 5.  Enhancing poxvirus vectors vaccine immunogenicity.

Authors:  Juan García-Arriaza; Mariano Esteban
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

6.  Quantitative and qualitative features of heterologous virus-vector-induced antigen-specific CD8+ T cells against Trypanosoma cruzi infection.

Authors:  Eiji Takayama; Takeshi Ono; Elena Carnero; Saori Umemoto; Yoko Yamaguchi; Atsuhiro Kanayama; Takemi Oguma; Yasuhiro Takashima; Takushi Tadakuma; Adolfo García-Sastre; Yasushi Miyahira
Journal:  Int J Parasitol       Date:  2010-07-08       Impact factor: 3.981

7.  Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine.

Authors:  J C Ramírez; M M Gherardi; M Esteban
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

8.  CD8+ T-cell mediated anti-malaria protection induced by malaria vaccines; assessment of hepatic CD8+ T cells by SCBC assay.

Authors:  Jing Zhou; Alaina Kaiser; Colin Ng; Rachel Karcher; Tim McConnell; Patrick Paczkowski; Cristina Fernandez; Min Zhang; Sean Mackay; Moriya Tsuji
Journal:  Hum Vaccin Immunother       Date:  2017-07-03       Impact factor: 3.452

Review 9.  Reflections on the early development of poxvirus vectors.

Authors:  Bernard Moss
Journal:  Vaccine       Date:  2013-04-10       Impact factor: 3.641

10.  Induction of protective immunity against malaria by priming-boosting immunization with recombinant cold-adapted influenza and modified vaccinia Ankara viruses expressing a CD8+-T-cell epitope derived from the circumsporozoite protein of Plasmodium yoelii.

Authors:  Gloria González-Aseguinolaza; Yurie Nakaya; Alberto Molano; Edward Dy; Mariano Esteban; Dolores Rodríguez; Juan Ramón Rodríguez; Peter Palese; Adolfo García-Sastre; Ruth S Nussenzweig
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.